CRP and infection: Disease Worsening: Few patients receiving UPA experienced worsening of disease following GC discontinuation (1% CDAI increase >2; 7% DAS28-CRP increase >0.6), and none on ADA experienced worsening. GC Reintroduction: GCs were reintroduced in 14% of patients on UPA and 19% on ADA. Serious Infection Rates: Rates of severe infection before and after GC discontinuation were 0.8 (95% CI 0.0-4.2) and 1.5 (0.2-5.4) events per 100 patient-years for UPA and 7.7 (1.6-22.4) and 0 E/100 PY for ADA, respectively.